Psilocybin and Depression Study

If you are between 19-65 years of age with mild-moderate Major Depressive Disorder (depression) and are currently taking selective-serotonin reuptake inhibitors (SSRIs), you may be eligible to participate in a study involving psilocybin-assisted therapy.

The purpose of this study is to evaluate whether the  length of time someone has been taking SSRIs has an effect on their response to psilocybin-assisted therapy. The study drug, psilocybin, is naturally derived from certain types of mushrooms with psychoactive properties (magic mushrooms). In previous studies, psilocybin-assisted therapy demonstrated the potential to improve mood and anxiety, including depression.

All study-related care will be provided at no cost.

What the study will include

• Pre-screening phone interview
• Screening visit: to determine eligibility
• 3 pre-dose preparatory therapy sessions, a single psilocybin (25mg) dosing session, and 3 post-dose integration therapy sessions over 12 weeks
• Wearing a fitness tracking device for 1 month
• 5 assessment sessions including blood draws, questionnaires, and depression assessments

Eligibility:

You may qualify as a study participant if:

• You are experiencing mild-moderate depressive symptoms
• You are on a stable dose of SSRIs (for at least 6 weeks)
• You have not used psychoactive substances (e.g., psilocybin, MDMA, LSD) in the last two months

Location:

The study requires you to participate in-person in Abbotsford, British Columbia.

More study information:

Effect of SSRIs on Response to Psilocybin Therapy

Contact:

Phone number: 778-584-0064
Email: [email protected]

Site Principal Investigator (Study Doctor):